Europe: Financing rounds for Haya, Lyrus, ADA Health and

Switzerland: Haya Therapeutics, a company developing medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the close of its Sfr18m (US$20m) seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, Bernina BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator. Haya also announced that Robert Williamson will join…

You must be a HMI Subscriber to view this content.

Subscribe Now »